AirSculpt Technologies (NASDAQ:AIRS) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of AirSculpt Technologies (NASDAQ:AIRS) from a sell rating to a hold rating in a research note published on Sunday.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of AirSculpt Technologies in a research report on Monday, December 29th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Reduce” and an average price target of $6.00.

AirSculpt Technologies Price Performance

NASDAQ:AIRS opened at $3.17 on Friday. The company has a market cap of $223.64 million, a PE ratio of -16.68 and a beta of 2.22. AirSculpt Technologies has a twelve month low of $1.51 and a twelve month high of $12.00. The company has a current ratio of 0.51, a quick ratio of 0.51 and a debt-to-equity ratio of 0.63. The company’s 50 day moving average is $2.34 and its two-hundred day moving average is $4.34.

AirSculpt Technologies (NASDAQ:AIRS) last issued its quarterly earnings results on Thursday, April 2nd. The company reported $0.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.05. AirSculpt Technologies had a negative net margin of 11.41% and a negative return on equity of 14.30%. The business had revenue of $33.44 million for the quarter, compared to analyst estimates of $34.93 million. During the same quarter in the prior year, the business posted ($0.09) EPS. AirSculpt Technologies’s revenue for the quarter was down 14.8% compared to the same quarter last year. Analysts anticipate that AirSculpt Technologies will post -0.01 EPS for the current year.

Insider Buying and Selling

In other AirSculpt Technologies news, major shareholder Jorey Chernett purchased 50,000 shares of the business’s stock in a transaction that occurred on Monday, March 23rd. The shares were bought at an average price of $2.91 per share, for a total transaction of $145,500.00. Following the acquisition, the insider owned 6,843,761 shares in the company, valued at $19,915,344.51. This represents a 0.74% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders purchased a total of 600,150 shares of company stock valued at $1,404,424 in the last 90 days. 76.58% of the stock is owned by corporate insiders.

Institutional Trading of AirSculpt Technologies

Several large investors have recently made changes to their positions in AIRS. Caitong International Asset Management Co. Ltd acquired a new stake in shares of AirSculpt Technologies in the fourth quarter worth $155,000. Aristides Capital LLC acquired a new position in AirSculpt Technologies during the fourth quarter valued at $140,000. Virtu Financial LLC acquired a new position in AirSculpt Technologies during the fourth quarter valued at $30,000. XTX Topco Ltd boosted its holdings in AirSculpt Technologies by 265.2% in the fourth quarter. XTX Topco Ltd now owns 179,813 shares of the company’s stock valued at $356,000 after purchasing an additional 130,581 shares during the last quarter. Finally, Tudor Investment Corp ET AL purchased a new stake in AirSculpt Technologies in the fourth quarter valued at $219,000. 91.54% of the stock is owned by hedge funds and other institutional investors.

AirSculpt Technologies Company Profile

AirSculpt Technologies, Inc (NASDAQ: AIRS) is a medical technology company specializing in minimally invasive body contouring. The company’s flagship AirSculpt® platform combines pneumatic power with precision microcannulas to deliver fat removal, transfer and sculpting procedures. AirSculpt Technologies partners with both company-owned and franchised cosmetic surgery practices to offer a streamlined, office-based alternative to traditional liposuction.

Through its proprietary system, AirSculpt Technologies provides both consumers and medical professionals with an integrated solution that emphasizes reduced downtime, smaller incision sites, and more predictable outcomes.